Plain language summary of the long-term (5 or more years) outcomes in the CARTITUDE-1 trial of ciltacabtagene autoleucel in people with relapsed or refractory multiple myeloma.

Для цитирования: Jagannath Sundar, Martin Thomas G, Lin Yi, Cohen Adam D, Raje Noopur, Htut Myo, Deol Abhinav, Agha Mounzer, Berdeja Jesus G, Lesokhin Alexander M, Liegel Jessica J, Rossi Adriana, Lieberman-Cribbin Alex, Usmani Saad Z, Dhakal Binod, Parekh Samir, Li Hui, Wang Feng, Montes de Oca Rocio, Plaks Vicki, Sun Huabin, Banerjee Arnob, Schecter Jordan M, Lendvai Nikoletta, Madduri Deepu, Lengil Tamar, Zhu Jieqing, Koneru Mythili, Akram Muhammad, Patel Nitin, Costa Filho Octavio, Jakubowiak Andrzej J, Voorhees Peter M. Plain language summary of the long-term (5 or more years) outcomes in the CARTITUDE-1 trial of ciltacabtagene autoleucel in people with relapsed or refractory multiple myeloma.. Future oncology (London, England). 2026. DOI: 10.1080/14796694.2026.2720305.